<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36846611</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Factors Associated With Long COVID Symptoms in an Online Cohort Study.</ArticleTitle><Pagination><StartPage>ofad047</StartPage><MedlinePgn>ofad047</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofad047</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofad047</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Few prospective studies of Long COVID risk factors have been conducted. The purpose of this study was to determine whether sociodemographic factors, lifestyle, or medical history preceding COVID-19 or characteristics of acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are associated with Long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In March 26, 2020, the COVID-19 Citizen Science study, an online cohort study, began enrolling participants with longitudinal assessment of symptoms before, during, and after SARS-CoV-2 infection. Adult participants who reported a positive SARS-CoV-2 test result before April 4, 2022 were surveyed for Long COVID symptoms. The primary outcome was at least 1 prevalent Long COVID symptom greater than 1 month after acute infection. Exposures of interest included age, sex, race/ethnicity, education, employment, socioeconomic status/financial insecurity, self-reported medical history, vaccination status, variant wave, number of acute symptoms, pre-COVID depression, anxiety, alcohol and drug use, sleep, and exercise.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 13 305 participants who reported a SARS-CoV-2 positive test, 1480 (11.1%) responded. Respondents' mean age was 53 and 1017 (69%) were female. Four hundred seventy-six (32.2%) participants reported Long COVID symptoms at a median 360 days after infection. In multivariable models, number of acute symptoms (odds ratio [OR], 1.30 per symptom; 95% confidence interval [CI], 1.20-1.40), lower socioeconomic status/financial insecurity (OR, 1.62; 95% CI, 1.02-2.63), preinfection depression (OR, 1.08; 95% CI, 1.01-1.16), and earlier variants (OR = 0.37 for Omicron compared with ancestral strain; 95% CI, 0.15-0.90) were associated with Long COVID symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Variant wave, severity of acute infection, lower socioeconomic status, and pre-existing depression are associated with Long COVID symptoms.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-7612-3352</Identifier><AffiliationInfo><Affiliation>Division of Cardiology at ZSFG, and Department of Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0585-6230</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Disease, Global Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyser</LastName><ForeName>Noah D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Sara J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djibo</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CVS Health Clinical Trial Services, Blue Bell, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khatib</LastName><ForeName>Rasha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Advocate Aurora Research Institute, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitzman</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Baylor Scott and White Health and Wellness Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Excellence in Health Equity, Center for Healthful Behavior Change, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isasi</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2700-9593</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carton</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Louisiana Public Health Institute, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olgin</LastName><ForeName>Jeffrey E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletcher</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beatty</LastName><ForeName>Alexis L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2022 Dec 06:2022.12.01.22282987. doi: 10.1101/2022.12.01.22282987</RefSource><PMID Version="1">36523412</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Post-Acute Sequelae of SARS-CoV-2 (PASC)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">patient-reported outcomes</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. MJPe has received consulting fees from Gilead Sciences and AstraZeneca and serves on a data safety monitoring board for American Gene Technologies. AD is employed by CVS Health. EO has received research funding to their institution from Pfizer. HK is a consultant for Novo Nordisk. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36846611</ArticleId><ArticleId IdType="pmc">PMC9945931</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad047</ArticleId><ArticleId IdType="pii">ofad047</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peluso MJ, Kelly JD, Lu S, et al. . Persistence, magnitude, and patterns of postacute symptoms and quality of life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement. Open Forum Infect Dis 2022; 9:ofab640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators; Hanson WS, Abbafati C, et al. . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022; 328:1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021; 4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschtick JL, Titus AR, Slocum E, et al. . Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. Clin Infect Dis 2021; 73:2055&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240848</ArticleId><ArticleId IdType="pubmed">34007978</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 2021; 18:e1003773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ayoubkhani D, Pawelek P, Gaughan C. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. UK Office for National Statistics, Technical Article. London 2021. Released 16 September 2021. Accessed 29 April 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021</Citation></Reference><Reference><Citation>Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E. Post-acute sequelae of SARS-CoV-2 infection among adults aged &#x2265;18 years - Long Beach, California, April 1-December 10, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:1274&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445372</ArticleId><ArticleId IdType="pubmed">34529639</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun 2021; 12:6571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022; 28:1461&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, et al. . Outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland study. Nat Commun 2022; 13:5663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Liao X, Liu Z, et al. . Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study. Emerg Microbes Infect 2022; 11:2680&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9639507</ArticleId><ArticleId IdType="pubmed">36215047</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Pinto MD, Borelli JL, et al. . COVID symptoms, symptom clusters, and predictors for becoming a long-hauler looking for clarity in the haze of the pandemic. Clin Nurs Res 2022; 31:1390&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510954</ArticleId><ArticleId IdType="pubmed">36154716</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill E, Mehta H, Sharma S, et al. . Risk Factors Associated with Post-Acute Sequelae of SARS-CoV-2 in an EHR Cohort: A National COVID Cohort Collaborative (N3C) Analysis as part of the NIH RECOVER program [preprint]. medRxiv. 2022. doi:10.1101/2022.08.15.22278603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.15.22278603</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594:259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. . Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022; 5:e2238804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Ailshire JA, Crimmins EM. Long COVID and symptom trajectory in a representative sample of Americans in the first year of the pandemic. Sci Rep 2022; 12:11647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9264749</ArticleId><ArticleId IdType="pubmed">35804058</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty AL, Peyser ND, Butcher XE, et al. . The COVID-19 citizen science study: protocol for a longitudinal digital health cohort study. JMIR Res Protoc 2021; 10:e28169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8407439</ArticleId><ArticleId IdType="pubmed">34310336</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147:573&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring AS, Tenforde MW, Chappell JD, et al. . Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 2022; 376:e069761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905308</ArticleId><ArticleId IdType="pubmed">35264324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord 2009; 114:163&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">18752852</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing generalized anxiety disorder. Arch Intern Med 2006; 166:1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler N, Singh-Manoux A, Schwartz J, Stewart J, Matthews K, Marmot MG. Social status and health: a comparison of British civil servants in Whitehall-II with European- and African-Americans in CARDIA. Soc Sci Med 2008; 66:1034&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">18180089</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Cancela-Cilleruelo I, Rodr&#xed;guez-Jim&#xe9;nez J, et al. . Associated-onset symptoms and post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with Wuhan, alpha or Delta SARS-CoV-2 variant. Pathogens 2022; 11(7). doi: 10.3390/pathogens11070725.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11070725</ArticleId><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci M, Graziani L, Tilli M, et al. . Infection with SARS-CoV-2 variants is associated with different long COVID phenotypes. Viruses 2022; 14:2367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9698829</ArticleId><ArticleId IdType="pubmed">36366465</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022; 399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka S, Tsuzuki S, Suzuki M, et al. . Post COVID-19 condition of the omicron variant of SARS-CoV-2. J Infect Chemother 2022; 28:1546&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9365517</ArticleId><ArticleId IdType="pubmed">35963600</ArticleId></ArticleIdList></Reference><Reference><Citation>Case KR, Wang CP, Hosek MG, et al. . Health-related quality of life and social determinants of health following COVID-19 infection in a predominantly Latino population. J Patient Rep Outcomes. 2022; 6:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9219362</ArticleId><ArticleId IdType="pubmed">35737279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller MC, Liang CJ, Marques AR, et al. . A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022; 175:969&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Quan L, Chavarro JE, et al. . Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions. JAMA Psychiatry. 2022; 79:1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9453634</ArticleId><ArticleId IdType="pubmed">36069885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, Palladini M, Villa G, De Lorenzo R, Rovere Querini P, Benedetti F. Prevalence, trajectory over time, and risk factor of post-COVID-19 fatigue. J Psychiatr Res 2022; 155:112&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9391361</ArticleId><ArticleId IdType="pubmed">36029623</ArticleId></ArticleIdList></Reference><Reference><Citation>Margalit I, Yelin D, Sagi M, et al. . Risk factors and multidimensional assessment of long COVID fatigue: a nested case-control study. Clin Infect Dis 2022; 75:1688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383780</ArticleId><ArticleId IdType="pubmed">35403679</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze EJ, Mattar C, Zorumski CF, et al. . Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020; 324:2292&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. . Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022;10:e42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long COVID cohort; an interventional pre-post study. Brain Behav Immun Health 2022; 24:100485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet U, Juckel G. COVID-19 outcomes: does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants-A scoping review. J Clin Psychopharmacol 2022; 42:284&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9042214</ArticleId><ArticleId IdType="pubmed">35420565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>